Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Novo Nordisk (NYSE:NVO) has drawn investor attention after recent share price moves, with the stock showing a monthly gain alongside weaker past 3 months and 1 year total returns, prompting closer examination of its fundamentals.
See our latest analysis for Novo Nordisk.
The recent rebound, including a 14.9% 1 month share price return and a 9.6% 7 day share price return, comes after weaker longer term total shareholder returns. As a result, the momentum currently appears more like a short term recovery than a firmly established trend.
If you are comparing Novo Nordisk with other opportunities in healthcare and AI, it can be useful to see which peers are catching attention through the 33 healthcare AI stocks
With Novo Nordisk trading at $42.22, an implied analyst value around $47.71 and an estimated intrinsic value gap of about 62%, the key question is whether this rebound signals a genuine buying window or whether the market is already pricing in future growth.
Most Popular Narrative: 55.6% Undervalued
According to the most widely followed narrative on Novo Nordisk, a fair value of about $95 per ADR sits well above the recent $42.22 close, framing the current rebound as a valuation reset rather than a finished story.
Novo Nordisk (NVO) has continued to face a tougher near-term backdrop, but the longer-term investment case remains intact. Management has narrowed 2025 guidance to 8 to 11% sales growth and 4 to 7% operating profit growth (constant exchange rates), explicitly citing intensifying competition and pricing pressure in both diabetes and obesity.
Curious what underpins that near $95 fair value? The narrative leans on resilient profitability, measured revenue growth, and a future earnings multiple that assumes the GLP-1 franchise keeps pulling more weight.
Result: Fair Value of $95 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this view can be challenged if pricing pressure in key GLP-1 markets intensifies further or if competing obesity and diabetes treatments gain faster traction than expected.
Find out about the key risks to this Novo Nordisk narrative.
Next Steps
With both risks and rewards on the table, the story around Novo Nordisk is far from one sided. Take a moment to review the key numbers, pressure points, and upside drivers for yourself, then round out your view with the 3 key rewards and 3 important warning signs
Ready to scout your next ideas?
If Novo Nordisk is on your radar, do not stop there. Broaden your watchlist now so you are not relying on a single storyline.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NVO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com